News Release

Yamanouchi Pharmaceutical Co., Ltd.

Opening extended Research and Development facilities of Yamanouchi Europe.

11 June,1999

On 11 June 1999 the extended Research and Development facilities of Yamanouchi Europe B.V.were officially opened in Leiderdorp by Dr. T. Takenaka, Managing Director and member of the Board of Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, Japan), responsible for Yamanouchi's R&D activities.

Yamanouchi Pharmaceutical Co., Ltd.
Yamanouchi is a research based pharmaceutical company with its headquarters in Japan, and with world wide activities in the discovery, development, production and marketing of innovative medicines. In total more than 8,000 people work for Yamanouchi, including 1,500 R&D-staff.

Yamanouchi Research and Development facilities in Leiderdorp
Since 1994, the R&D facilities of Yamanouchi Europe have been located in Leiderdorp. As part of the global development of pharmaceutical products, the European facility performs preclinical and clinical studies in close cooperation with the mother company in Japan and with Yamanouchi USA.
The laboratory facilities for in particular bioanalysis, in-vitro drug metabolism and pharmaceutical studies needed expansion. Also the in-house clinical pharmacology unit (CPU) lacked sufficient space to cope with the increasing demand of phase I studies on new compounds originating from Yamanouchi's drug discovery institute in Tsukuba, Japan. Therefore, the existing building was expanded with a new wing in which a significant part is dedicated to an extended and upgraded CPU with 14 beds and state-of-the-art equipment.
In the field of advanced drug delivery and drug targeting Yamanouchi collaborates closely with the Dutch Universities of Groningen, Leiden and Utrecht in the UNYPHAR project.

Yamanouchi Europe
The headquarters of Yamanouchi Europe, and the Dutch marketing and sales organisation in The Netherlands, are located in Leiderdorp (The Netherlands). Yamanouchi Europe also has subsidiaries in most European countries for local marketing and sales of the company's products. Production facilities are situated in Meppel (The Netherlands) and Carugate (Italy). Yamanouchi Europe has a staff of 1600.

The main products currently marketed by Yamanouchi in Europe are Omnic® (Omic®, Flomax®), Locoid®, Flemoxin Solutab® and Pentasa®.